Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/Pathologyblue cross blue shield kansas Vitamin D Coverage U…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedblue cross blue shield - kansasPolicy N/A

    Testing Serum Vitamin D Levels

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when measurement of serum 25-hydroxyvitamin D is considered medically necessary, investigational, or routine screening for Blue Cross and Blue Shield of Kansas members; it applies to clinicians ordering vitamin D testing for insured members.

    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyTesting Serum Vitamin D Levels
    Policy CodePolicy N/A
    Change TypeRevised policy statements (C and D) to experimental/investigational
    Effective DateFeb 26, 2026
    Last ReviewFeb 26, 2026
    Next Review DateFeb 26, 2026
    Key ActionVerify member benefits and any applicable prior authorization per the member's contract and BCBSKS customer service before ordering testing.
    SourceLink
    POLICY UPDATE CHANGES

    Changed Policy Statement C and D from not medically necessary to experimental / investigational.

    02-26-2026Most recent effective date for material change
    No RCTsDirect RCTs testing vs no testing
    15High-risk factors listed
    3Codes listed
    ACOG/Endocrine/USPSTF/BHOFGuideline citations

    Coverage Criteria and Evidence Summary

    Medically necessary — high-risk conditions

    Covered when ANY of the following high-risk conditions or scenarios are present

    High-risk conditions for medically necessary testing

    • Listed high-risk factors: 1. Chronic kidney disease, stage >=3; 2. Granulomatous diseases; 3. Parathyroid disorders; 4. Cirrhosis and chronic liver disease; 5. Malabsorption states; 6. Chronic use of anticonvulsant medications or systemic corticosteroids; 7. Osteomalacia; 8. Osteopenia; 9. Osteoporosis; 10. Rickets; 11. Vitamin D deficiency, on replacement; 12. Hypo- or hypercalcemia; 13. Obstructive jaundice/biliary tract disease; 14. Osteogenesis imperfecta; 15. Osteosclerosis and osteopetrosis.

      From Policy Item A in the document.

    Medically necessary — asymptomatic but at-risk or institutionalized

    Covered in asymptomatic individuals when ALL of the following apply

    Asymptomatic individuals at-risk or institutionalized

    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyTesting Serum Vitamin D Levels
    Policy CodePolicy N/A
    Change TypeRevised policy statements (C and D) to experimental/investigational
    Effective DateFeb 26, 2026
    Last ReviewFeb 26, 2026
    Next Review DateFeb 26, 2026
    Key ActionVerify member benefits and any applicable prior authorization per the member's contract and BCBSKS customer service before ordering testing.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummaryIndications When Testing Is CoveredNot Covered / Excluded IndicationsProcedure and Diagnosis CodesProvider Actions, Documentation, and Billing NotesOrdering Requirements and FrequencyKey DefinitionsBackground and RationaleRevision and Policy Changes
    Population conditions: 1) The individual has one or more risk factors for vitamin D deficiency (as listed under high-risk factors); AND 2) The individual is institutionalized (resides in a long-term care facility, long-term hospital stay, nursing home, assisted living, or similar setting).

    Institutionalized defined in Policy Guidelines.

    Experimental / Investigational / Routine screening — Not covered / investigational

    Not covered / investigational

    Investigational or routine screening: Testing vitamin D levels in asymptomatic individuals is considered experimental/investigational when criteria in Items A or B are not met; routine population screening for vitamin D deficiency is considered experimental/investigational and not covered.

    Policy Items C and D.

    Overall clinical utility

    General evidence summary relevant to coverage decisions

    Clinical utility premise: A diagnostic test for vitamin D is clinically useful only if testing changes management and improves net health outcomes; no randomized controlled trials were identified that directly compare testing versus no testing, so evidence of supplementation benefit is indirect and must be extrapolated to justify testing when baseline 25(OH)D predicts treatment response.

    Analytic framework and 'Clinically Useful' summary.

    Skeletal health

    Skeletal health-specific findings relevant to coverage

    Skeletal outcomes evidence: Randomized trials and meta-analyses report inconsistent effects of vitamin D supplementation on fractures and falls; some analyses show benefit at doses around 700–800 IU/day in select subgroups (eg, elderly institutionalized women), whereas very high or certain bolus regimens may increase fall risk; trials that selected deficient patients did not consistently demonstrate fracture reduction.

    Dose-response and subgroup signals noted; overall evidence not convincingly favorable.

    Cardiovascular disease

    Cardiovascular and other outcomes

    Cardiovascular outcomes evidence: Systematic reviews and randomized trials do not demonstrate a clear benefit of vitamin D supplementation on cardiovascular death, myocardial infarction, stroke, or key physiologic cardiovascular risk factors; cardiovascular outcomes were typically secondary endpoints with limited events and analyses may be confounded by concomitant calcium use.

    Evidence summarized in cardiovascular section.

    Cancer

    Cancer outcomes

    Cancer outcomes evidence: Systematic reviews of randomized trials generally found no reduction in cancer incidence with vitamin D supplementation; some analyses reported reduced total cancer mortality, but trials were not primarily designed for cancer endpoints and subgroup findings are at risk of type I error.

    Cancer section summary.

    Evidence-based considerations for testing

    Guidance and evidence summaries relevant to when testing or supplementation may be considered:

    Pregnancy guidance and evidence: Systematic reviews and RCTs suggest vitamin D supplementation during pregnancy may reduce some adverse maternal and neonatal outcomes (eg, gestational diabetes, low birth weight, severe postpartum hemorrhage) in some analyses; ACOG states insufficient evidence to recommend universal screening but allows testing for pregnant women thought to be at increased risk and recommends interpretation on an individual basis.

    ACOG committee opinion and pregnancy evidence summary.

    Multiple Sclerosis and other conditions: Some meta-analyses report potential benefits of vitamin D supplementation on selected disease-specific measures (eg, MS disability scores), but clinical endpoint results are inconsistent and not conclusive for routine testing purposes.

    Condition-specific evidence varies.

    Guideline screening stance: Professional guidelines differ: the Endocrine Society (2024) suggests against routine testing in general adult populations and pregnant individuals without other indications; the USPSTF (2021) found insufficient evidence to recommend screening asymptomatic individuals; BHOF recommends monitoring in older adults for bone health to maintain specified serum targets.

    Guideline positions summarized.

    Policy statement changes

    Policy scope and notable policy statement changes (partial content from this document segment):

    Policy statement changes: Policy statements C and D were changed from 'not medically necessary' to 'experimental / investigational' effective 02-26-2026; historical revisions added and revised listed high-risk conditions and asymptomatic testing allowances over time.

    Revision history entries document these changes.

    Routine population screening for vitamin D deficiency (testing asymptomatic individuals with no listed risk factors or institutionalization) is considered experimental/investigational and is excluded from coverage under this policy. The policy specifies that testing is medically necessary only when one of the defined high‑risk factors is present or when asymptomatic individuals meet the policy’s specific at‑risk or institutionalized criteria; otherwise routine screening is not covered.

    There is no accepted reference standard or consensus cutoffs for defining vitamin D deficiency. Available 25‑hydroxyvitamin D (25[OH]D) cutoffs are not standardized and are not based on rigorous studies, so test sensitivities and specificities for detecting clinically important deficiency are currently unknown. This lack of a clear, validated threshold limits the use of single numeric test results as absolute criteria for coverage decisions.

    Systematic reviews and randomized trials do not demonstrate that vitamin D supplementation reduces cancer incidence. The policy’s evidence summary states that current trials and meta‑analyses do not support supplementation for cancer prevention, and cited randomized studies did not show a consistent reduction in cancer incidence.

    Recent guideline statements summarized in the policy recommend against universal screening. The Endocrine Society (2024) suggests against routine testing of 25(OH)D in general adult populations and in pregnant individuals who do not have other established indications, and the American College of Obstetricians and Gynecologists (ACOG) states there is insufficient evidence to recommend screening all pregnant women, advising testing be reserved for those thought to be at increased risk and interpreted individually.

    Historic policy language documented in revisions previously described testing vitamin D levels in asymptomatic patients as not medically necessary when the enumerated criteria were not met. The revision history shows the addition of Item C (historic wording) and describes multiple past edits to Item A and B that defined covered patient populations and the prior not‑medically‑necessary stance for routine asymptomatic testing.

    In the references‑only portion of the provided excerpt there are no explicit coverage exclusions enumerated beyond the policy statements themselves. The document does reference external guidance and a Noridian Local Coverage Determination (LCD L36692) for vitamin D assay testing for billing/coverage rules, but the reference list segment does not list additional explicit exclusions.

    Testing asymptomatic individuals who do not meet the policy’s listed risk factors and who are not institutionalized is considered experimental/investigational and therefore not medically necessary under this policy. The policy explicitly states that testing in asymptomatic individuals is investigational when criteria in Items A and B are not met, reflecting the absence of direct evidence that routine testing improves clinical outcomes.

    Routine testing of asymptomatic individuals lacks randomized controlled trial evidence showing that testing versus not testing improves clinical outcomes; therefore, routine screening in asymptomatic populations is judged to lack direct evidence of clinical benefit and may be considered investigational. The policy frames testing as clinically useful only when results will inform management decisions that improve net health outcomes.

    The evidence summarized in this policy does not support the use of vitamin D supplementation specifically to prevent cancer incidence. Systematic reviews of RCTs noted that cancer outcomes were often not primary endpoints and, overall, did not demonstrate a reduction in incident cancer with vitamin D supplementation.

    The policy cites professional guidance consistent with a non‑screening stance: the Endocrine Society (2024) recommends against routine 25(OH)D testing in several general adult populations and in pregnant individuals without indications, and ACOG (2011, reaffirmed 2024) advises that universal screening in pregnancy is not supported by current evidence and that testing should be individualized for those at increased risk.

    Historic policy language within the document previously stated that testing vitamin D levels in asymptomatic patients was not medically necessary when the listed criteria were not met. Revision history entries document the addition of the not‑medically‑necessary language and prior changes to the policy items that defined covered and excluded populations.

    Within the provided references‑only excerpt there are no explicit 'not medically necessary' statements beyond the policy body and its revision history; the reference list itself does not restate coverage determinations. For specific not‑medically‑necessary language, refer to the Policy section and the revision history entries.

    Indications When Testing Is Covered

    Diagnostic testing for suspected vitamin D deficiency or toxicity in symptomatic individuals when a listed high-risk condition is present; testing in asymptomatic individuals who are at risk or institutionalized

    Covered indications — symptomatic or high-risk: Diagnostic testing for suspected vitamin D deficiency or toxicity is covered in symptomatic individuals when one or more listed high-risk conditions are present; signs/symptoms related to bone health or biochemical abnormalities (eg, unexplained calcium, phosphorus, alkaline phosphatase, or parathyroid hormone) support testing.

    Laboratory covered indications Item A and Policy Guidelines.

    Covered indications — asymptomatic but at-risk/institutionalized: Testing may be covered in asymptomatic individuals when results would change management: individuals with listed risk factors and institutionalized individuals as specified in Item B.

    Laboratory covered indications Item B.

    Assessment when results would change management

    Assessment when results would change management: Testing is appropriate when the clinical context is such that measured 25(OH)D results would alter treatment decisions (for example, suspected deficiency in symptomatic or high-risk patients where supplementation or treatment intensity depends on baseline level).

    No RCTs comparing testing vs no testing; clinical utility must be inferred from supplementation trials and management implications.

    Assessment of baseline 25(OH)D status when evaluating need for supplementation or interpreting trial applicability

    Baseline 25(OH)D assessment: Baseline measurement of serum 25(OH)D may be appropriate when interpreting trial applicability or when deciding on supplementation dosing because some trial subgroup effects were observed in participants with low baseline 25(OH)D levels.

    Many trials did not select patients by baseline 25(OH)D; documentation of baseline level is recommended when used to guide therapy.

    Assessment of vitamin D status in research or clinical contexts related to asthma or pregnancy outcomes

    Research and condition-specific assessment: Measurement of vitamin D status may be appropriate in research or selected clinical contexts related to asthma or pregnancy outcomes where trial data inform management or interpretation; many trials did not measure baseline 25(OH)D and populations were not selected for low baseline levels, limiting generalizability.

    Asthma and pregnancy sections reference multiple RCTs and reviews.

    Pregnancy with increased risk for vitamin D deficiency, postmenopausal women and men 50+ for bone health monitoring, and other condition-specific indications supported by evidence or specialty guidance

    Pregnancy, older adults, and other condition-specific indications: Testing may be considered for pregnant individuals at increased risk for deficiency (ACOG allows individualized testing), for postmenopausal women and men >=50 for bone health monitoring (BHOF recommends monitoring to maintain 30–50 ng/mL), and for other specific conditions where evidence or specialty guidance support assessment (eg, identified deficiency, MS management).

    Guideline-based and evidence-based indications summarized.

    Testing in individuals with risk factors for vitamin D deficiency or specific listed clinical conditions (as outlined historically)

    Testing for listed clinical conditions historically included: Testing is indicated in individuals with risk factors or specific clinical conditions historically added to Item A (examples include cirrhosis/chronic liver disease, chronic use of anticonvulsants or systemic corticosteroids, osteogenesis imperfecta, osteosclerosis/osteopetrosis, hypo- or hypercalcemia, obstructive jaundice/biliary tract disease).

    Revisions documented in the policy history.

    Pregnancy and lactation — multiple randomized trials and reviews assessing vitamin D supplementation effects on maternal and neonatal outcomes are cited

    Pregnancy and lactation evidence: Multiple randomized trials and systematic reviews of vitamin D supplementation in pregnancy and lactation are cited; these examine maternal and neonatal serum levels, gestational diabetes, pre-eclampsia, birthweight, and infant outcomes and inform when testing or supplementation may be considered in high-risk pregnant populations.

    Refer to pregnancy evidence tables and systematic reviews cited.

    Asthma and respiratory disease — trials and meta-analyses on vitamin D supplementation for prevention or management of exacerbations and asthma control

    Asthma and respiratory disease evidence: Systematic reviews and randomized trials assessing vitamin D supplementation for asthma and respiratory outcomes are summarized; findings are mixed and baseline 25(OH)D selection varied, so testing may be considered in contexts where deficiency status would alter management or trial interpretation.

    Multiple SRs and RCTs cited in asthma sections.

    Bone health, fractures, falls, cancer, cardiovascular and metabolic outcomes — numerous trials cited investigating supplementation effects

    Broad outcomes evidence: Numerous trials investigating supplementation effects on bone health (fractures, falls), cancer, cardiovascular, and metabolic outcomes are cited; overall evidence does not consistently demonstrate benefit for these endpoints and therefore does not support routine population screening for vitamin D status.

    References cited span older adults and community populations.

    Screening, diagnosis, and monitoring of vitamin D status as referenced by cited guidelines and trials

    Screening, diagnosis, and monitoring guidance: Screening, diagnostic thresholds, and monitoring recommendations are informed by cited guidelines and trials (eg, ACOG, Endocrine Society, BHOF, USPSTF); specific covered indications for screening and monitoring should align with these guideline recommendations and the referenced Noridian LCD where applicable.

    Guidelines and LCD cited in references.

    Not Covered / Excluded Indications

    The policy’s Not Covered summary states that routine population screening of asymptomatic individuals without risk factors or institutionalization is not covered and is considered experimental/investigational. This aligns with the policy language that testing of asymptomatic individuals is investigational when policy criteria for medical necessity are not met.

    The policy emphasizes that there are no randomized trials demonstrating that testing for vitamin D deficiency versus not testing improves clinical outcomes; as a result, routine screening of the asymptomatic general population is not supported by direct evidence of benefit. This evidence gap underpins the not‑covered stance for routine population screening.

    The evidence summarized in the policy does not support routine testing or supplementation solely for cancer prevention. Systematic reviews and RCTs cited in the references do not show a consistent reduction in cancer incidence attributable to vitamin D supplementation, and the policy therefore does not endorse testing for the purpose of cancer prevention.

    Guideline statements referenced in the policy do not support universal screening: the Endocrine Society suggests against routine testing in general adult populations and pregnant individuals without indications, and ACOG states insufficient evidence to recommend universal pregnancy screening. These guideline positions support the policy’s not‑covered conclusions for routine screening in asymptomatic adults and pregnant individuals without other indications.

    The policy’s historical language previously characterized testing in asymptomatic patients without risk factors as not medically necessary, and portions of those statements were revised; the revision history documents changes including the 02‑26‑2026 change of Policy Statements C and D from 'not medically necessary' to 'experimental/investigational.'

    The provided references segment does not enumerate specific tests or indications labeled explicitly as not covered; in this excerpt there are no explicit not‑covered test lists. The policy body and laboratory not‑covered section supply the coverage stance for routine screening.

    No explicit exclusions are listed in the references excerpt itself; the policy references external guidance and the Noridian LCD (L36692) for vitamin D assay testing. Providers should refer to the full policy text and the Noridian LCD for any explicit exclusions or billing rules not present in this excerpt.

    Procedure and Diagnosis Codes

    Included Procedure CodesCPT | HCPCS
    82306Vitamin D; 25 hydroxy, includes fraction(s), if performed
    82652Dihydroxyvitamin D, 1, 25 dihydroxy, includes fraction(s), if performed
    0038UVitamin D, 25 hydroxy D2 and D3, by LCMS/MS, serum microsample, quantitative
    Covered CPT/HCPCS Codes (when performed per Policy)CPTCovered
    82306Vitamin D; 25 hydroxy, includes fraction(s), if performed.
    82652Dihydroxyvitamin D, 1,25 dihydroxy, includes fraction(s), if performed.
    0038UVitamin D, 25 hydroxy D2 and D3, by LCMS/MS, serum microsample, quantitative
    ICD-10 Diagnosis Codes (historic revisions)ICD-10
    multiple ICD-10 codes and rangesNumerous ICD-10 diagnosis codes have been added, removed, or revised across policy updates; see Coding section revision history for specific codes and effective dates.
    Referenced LCD / Coverage Codemixed
    L36692Noridian LCD: Vitamin D Assay Testing (referenced as local coverage determination)

    Provider Actions, Documentation, and Billing Notes

    Prior Authorization

    Benefit verification required

    Verify the member's benefits and any applicable prior authorization requirements with BCBSKS Customer Service and the member's contract before ordering vitamin D testing.

    • Check member contract language for coverage or exclusions.
    • Contact BCBSKS Customer Service for benefit verification and prior authorization rules.
    Prior Authorization

    Prior authorization considerations

    Recognize that no randomized controlled trials directly compare testing versus no testing; use evidence from supplementation trials only as indirect support when determining whether testing will change management.

    • Order testing only when results are expected to influence clinical management.
    • Document clinical rationale linking testing to a management decision.
    Note

    No prior auth specified

    No prior authorization requirements are specified within the policy text; however, benefit verification per the member contract remains necessary.

    • Absence of a stated PA in this policy does not waive member-contract PA rules.
    • Confirm with payer if local plan or LCD imposes PA.
    Note

    Prior authorization not addressed in this excerpt

    The evidence-summary sections do not specify prior authorization requirements; they summarize clinical evidence and policy stance rather than PA procedures.

    • Clinical evidence summaries should not be interpreted as PA policy.
    • Follow member contract and payer PA processes.
    Billing Rule

    Coding and medical necessity

    CPT/HCPCS codes for vitamin D testing (82306, 82652, 0038U) are listed in the Coding section and are considered medically necessary only when the test is performed according to the Policy section.

    • 82306 — Vitamin D; 25 hydroxy, includes fraction(s), if performed.
    • 82652 — Dihydroxyvitamin D, 1,25 dihydroxy, includes fraction(s), if performed.
    • 0038U — Vitamin D, 25 hydroxy D2 and D3, by LCMS/MS, serum microsample, quantitative.
    Billing Rule

    Coding tied to policy coverage

    The policy ties listed CPT/HCPCS codes to the Policy section: these codes are medically necessary only when testing meets the Policy's clinical criteria and any applicable member contract rules.

    • Do not assume code inclusion guarantees reimbursement; ensure indication aligns with Policy criteria.
    • Document how the test meets the Policy to support billing.
    Note

    Prior authorization (not specified in this segment)

    The policy references external citations but does not describe prior authorization in the reference list; verify PA requirements separately per contract and payer processes.

    • Reference lists do not substitute for PA policy statements.
    • Confirm any PA rules that may be in source documents or LCDs.
    Prior Authorization

    Follow Noridian LCD for coverage requirements

    Follow Noridian Local Coverage Determination (LCD L36692) for Vitamin D Assay Testing where applicable; LCD requirements for prior authorization or billing may apply and failure to meet LCD requirements could lead to claim denial.

    • Consult LCD L36692 for coverage and billing rules when Medicare or LCD jurisdiction applies.
    • Ensure documentation meets any LCD-specified criteria.
    Step Therapy

    Step therapy

    No step therapy requirements are specified in this policy excerpt.

    • No prerequisite treatments or trials are mandated by this document before testing.
    Step Therapy

    Dose and safety considerations

    Evidence on vitamin D supplementation includes dose-response and safety signals (for example, some very high-dose regimens increased falls); consider these safety findings when planning supplementation and when interpreting the need for testing.

    • Trials reported reduced fractures with 700–800 IU/day in some analyses, while very high or certain bolus regimens were associated with increased falls or fractures.
    • Use trial dosing and safety data to inform clinical decisions rather than assuming higher dosing is safer.
    Documentation Required

    Required documentation

    Document clinical signs/symptoms, the relevant diagnosis or high-risk condition, and any pertinent biochemical abnormalities (e.g., unexplained calcium, phosphorus, alkaline phosphatase, or parathyroid hormone) to support medical necessity for vitamin D testing.

    • Include clinical diagnosis (eg, osteomalacia, rickets, osteoporosis) or biochemical reason for testing.
    • Record benefit verification and any PA determinations in the medical record.
    Documentation Required

    Test validity and interpretation

    Recognize that there is no consensus reference standard or standardized cutoffs for 25(OH)D; document interpretation plans and acknowledge that available cutoffs are not universally validated.

    • State which cutoff or reference range is being used and why it applies to the patient.
    • Note limitations of test sensitivity and specificity in the record when relevant to coverage discussions.
    Documentation Required

    Baseline 25(OH)D reporting

    When baseline 25(OH)D levels are relevant to clinical decisions or to interpret trial applicability, document the baseline value in the medical record; many trials reported baseline levels and subgroup effects depended on baseline status.

    • Record pre-supplementation 25(OH)D when assessing need for supplementation or monitoring response.
    • Note if prior trials or guideline recommendations referenced baseline thresholds to guide therapy.
    Documentation Required

    Documentation requirement

    Include documentation demonstrating the test indication aligns with the Policy section (i.e., that the patient meets a listed high‑risk condition or is an at‑risk/institutionalized asymptomatic individual) to support medical necessity and billing.

    • Attach clinical notes showing the listed high-risk condition or reasons testing will change management.
    • Ensure the medical record supports the CPT/HCPCS code billed.
    Denial Risk

    Denial risk for screening or unsupported testing

    Testing vitamin D levels in asymptomatic individuals without the policy-listed risk factors or institutionalization carries a denial risk because such testing is considered experimental/investigational under this policy.

    • Order testing for asymptomatic patients only if they meet criteria in Item A or B of the Policy.
    • Anticipate claim denials if documentation does not show a listed indication.
    Denial Risk

    Lack of direct evidence for testing utility

    There are no randomized trials demonstrating that testing for vitamin D deficiency versus not testing improves clinical outcomes; this lack of direct evidence may be used to justify denials when testing is not clearly indicated.

    • Be prepared to justify how testing will alter management and improve outcomes when requesting authorization.
    • Cite clinical indication and expected management change in documentation to mitigate denial risk.
    Denial Risk

    Medical necessity tied to policy criteria

    The CPT/HCPCS codes listed in the policy do not by themselves guarantee coverage or reimbursement; the procedure must meet the Policy section criteria and member contract terms.

    • Do not rely on code listing alone—ensure clinical criteria are met and documented.
    • If denied, reference how the indication meets Policy criteria in an appeal.
    Note
    Note
    Note

    Ordering Requirements and Frequency

    Prior Authorization

    ORDERING: Verify member benefits

    Verify member benefits and follow member contract provisions when ordering tests; confirm prior authorization requirements with BCBSKS Customer Service as instructed in Policy Guidelines.

    Note

    ORDERING: Test when results will change management

    Order 25(OH)D testing only when results are expected to affect clinical management (for example symptomatic patients, those with listed high‑risk conditions, or asymptomatic but at‑risk/institutionalized individuals).

    • Testing appropriate when it will change management or guide supplementation
    • Use clinical context (signs/symptoms, biochemical markers, risk factors) to justify testing
    Note

    ORDERING: No provider-type restriction stated

    This excerpt does not impose specific ordering provider restrictions; follow local practice and member contract terms regarding who may order testing.

    Note

    ORDERING: Who may order and frequency not specified

    The provided excerpt does not specify who may order 25(OH)D testing or any frequency limits; rely on Policy Guidelines and member contract for such details.

    Note

    ORDERING: Clinician types not specified

    The policy excerpt does not specify clinician types that may order testing; guideline statements suggest clinicians managing pregnancy or bone health should consider testing when clinically indicated.

    Note

    ORDERING: Historic allowance for testing in at‑risk asymptomatic patients

    Historically, the policy allowed testing in certain asymptomatic populations with risk factors or institutionalized patients; document the specific risk factors or institutional status when ordering.

    • Item B allows testing in individuals with listed risk factors and institutionalized patients
    • Ensure documentation shows the patient meets Item A or B criteria
    Note

    ORDERING: No who‑can‑order restrictions in excerpt

    No 'who can order' restrictions are included in the provided references portion of the policy; follow local protocols and member contract rules.

    Note

    ORDERING: Liaison committee implications on ordering

    Liaison committee inputs from Internal Medicine, OB/GYN, and Family Practice suggest ordering is expected from primary care and specialty clinicians managing the listed conditions; document clinical rationale accordingly.

    25-hydroxyvitamin D frequency guidance
    Guidance summaryFrequency is variable: a single 25-hydroxyvitamin D test may be indicated for diagnosis, with repeat testing appropriate to assess response to supplementation or ongoing deficiency; more than one repeat test may be needed if supplementation fails or absorption/compliance concerns persist.
    When to repeatRepeat testing appropriate to determine whether supplementation restored normal serum levels or when ongoing signs/symptoms suggest persistent deficiency.
    Number of repeatsMore than one repeat test may occasionally be indicated (e.g., persistent deficiency, inadequate absorption, or noncompliance).
    Frequency limits not specified
    Frequency limits statedNot specified in this document segment; trials report dosing and supplement regimens rather than prescribing laboratory testing frequency.
    Trial reportingClinical trials cited used varied dosing schedules (weekly, monthly, yearly bolus regimens) rather than standardized lab monitoring intervals.
    Implication for practiceLaboratory monitoring intervals should be guided by clinical context and the supplementation regimen rather than a fixed policy frequency in this excerpt.
    Vitamin D assay (25-hydroxyvitamin D) — frequency
    Policy excerpt on frequencyFrequency limits are not specified in this excerpt for the vitamin D assay (25-hydroxyvitamin D).
    Coding referenceThe vitamin D assay (25-hydroxyvitamin D) is listed under procedure codes (CPT 82306 and related codes) but frequency rules are not provided here.
    Follow clinical judgmentOrdering frequency should follow clinical indication and guideline recommendations since the policy does not set fixed limits in this segment.
    Frequency limits — Not specified
    StatementFrequency limits are not specified in this segment of the document.
    Practice implicationClinicians should determine monitoring intervals based on clinical context, supplementation regimen, and guideline guidance.
    When monitoring may be neededConsider repeat testing when assessing response to therapy, persistent symptoms, or suspected malabsorption/noncompliance.

    Key Definitions

    25-hydroxyvitamin D
    Definition25-hydroxyvitamin D is the serum metabolite measured to assess vitamin D status and is considered the best available indicator of vitamin D deficiency.
    Physiologic roleVitamin D (calciferol) is a fat-soluble vitamin important for calcium homeostasis and bone metabolism and has additional physiologic effects.
    Consensus on cutoffsThere is no consensus on minimum or optimal serum levels; IOM (2011) considers 20 ng/mL sufficient for most healthy adults; some experts recommend higher targets in certain populations.
    Institutionalized
    Definition'Institutionalized' refers to individuals residing in long-term facilities where some degree of medical care is provided (e.g., long-term hospital stays, nursing homes, assisted living).
    Policy contextInstitutionalized status is a coverage qualifier for testing in asymptomatic individuals when combined with listed risk factors.
    ExamplesIncludes long-term hospital stays, nursing homes, assisted living facilities, and similar environments.
    Biomarker and test performance
    Biomarker descriptionTests measure total serum 25-hydroxyvitamin D (25[OH]D) to assess vitamin D status.
    Test performanceDiagnostic cutoffs are not standardized and sensitivities/specificities for clinically important deficiency are currently unknown.
    Reference standardThere is no accepted reference standard for defining vitamin D deficiency, limiting absolute threshold use.
    25(OH)D abbreviation
    Abbreviation25(OH)D = 25-hydroxyvitamin D, the circulating form measured to assess vitamin D status.
    UsageUsed throughout trials and guideline discussions as the standard analyte for vitamin D assessment.
    ReportingReported in clinical studies although baseline selection by low levels was often not performed.
    25-hydroxyvitamin D (study context)
    Clinical noteSerum 25-hydroxyvitamin D (25[OH]D) is the standard biomarker used to measure vitamin D status; many studies did not select patients by low baseline 25(OH)D or measure baseline levels.
    ImplicationAbsence of baseline selection limits applicability of trial results to deficient populations.
    Use in trials25(OH)D commonly measured as an outcome or baseline variable in pregnancy and asthma trials, but selection varied.
    25-hydroxyvitamin D referenced in coding
    Coding reference25-hydroxyvitamin D is referenced in the coding section as the analyte associated with CPT code 82306.
    Policy linkageThe analyte is the target of procedure coding and is central to the policy's laboratory coverage considerations.
    Testing methodsBoth immunoassays and LCMS/MS methods are used; coding distinguishes the general assay (82306) and specific LCMS/MS micropanel (0038U).
    CPT 82306
    CPT code82306: Vitamin D; 25 hydroxy, includes fraction(s), if performed.
    UseUsed to report measurement of serum 25-hydroxyvitamin D under this policy when performed per the Policy section.
    NotesInclusion in coding list does not by itself guarantee coverage — medical necessity must align with policy criteria.
    CPT 82652
    CPT code82652: Dihydroxyvitamin D, 1,25-dihydroxy, includes fraction(s), if performed.
    Clinical roleMeasures active form 1,25-dihydroxyvitamin D; code listed for informational purposes in the policy coding section.
    Coverage noteCodes are medically necessary ONLY if the procedure is performed according to this document's Policy section.
    CPT 0038U
    CPT code0038U: Vitamin D, 25 hydroxy D2 and D3, by LCMS/MS, serum microsample, quantitative.
    MethodSpecifies LCMS/MS measurement of D2 and D3 microsample; added to coding in revisions (see update history).
    Reporting contextListed in coding for informational purposes; medical necessity determined by policy criteria.
    25-hydroxyvitamin D — common biomarker
    Clinical prevalence25-hydroxyvitamin D is the biomarker commonly measured in clinical practice and research to assess vitamin D status.
    Measurement variabilityAssays measure total 25(OH)D but methodological differences and lack of standardized cutoffs affect interpretation.
    Research useWidely used across trials evaluating supplementation effects on bone, pregnancy, asthma, and other outcomes.
    25-hydroxyvitamin D referenced in guideline documents
    Guideline references25-hydroxyvitamin D (serum 25[OH]D) is referenced in multiple guideline documents cited by the policy (e.g., ACOG, Endocrine Society, USPSTF, AHRQ reviews).
    Policy relevanceGuideline recommendations inform when testing or monitoring may be appropriate (eg, pregnancy risk, older adults).
    LCD referenceNoridian LCD for Vitamin D Assay Testing is also cited and may guide coverage/billing decisions for the assay.

    Background and Rationale

    Vitamin D (calciferol) is a fat‑soluble vitamin important for calcium homeostasis and bone metabolism, and serum 25‑hydroxyvitamin D (25[OH]D) is the biomarker most commonly used to assess vitamin D status. Deficiency is common and can result from inadequate intake, limited sun exposure, malabsorption, or organ dysfunction; testing is intended to guide treatment decisions that improve net health outcomes.

    Revision and Policy Changes

    2026-02-26policy_revisionLatest

    Policy statements C and D were changed from 'not medically necessary' to 'experimental / investigational'.

    2016-10-01policy_revision

    Multiple Item A entries were added/modified (including adding chronic use of anticonvulsant medications or corticosteroids, adding hypo- or hypercalcemia, obstructive jaundice, osteogenesis imperfecta, osteosclerosis/osteopetrosis) and Items B and C were added clarifying asymptomatic testing criteria and a not medically necessary statement when criteria are not met.

    2022-02-25policy_update

    Updated Rationale and References sections and changed wording in Section C ('is' to 'are'); ICD-10 codes were changed to code ranges in the Coding section.

    2023-01-24policy_update

    Updated Description, Rationale, and References sections.

    2024-01-23policy_update

    Updated Description, Rationale, References, and Coding sections; removed certain ICD-10 codes.

    2025-01-28policy_update

    Updated Description, Rationale, and References sections.

    The references‑only segment reiterates that no explicit not‑covered tests are listed within that portion. The policy text and revision history provide the applicable coverage and not‑covered statements; for additional exclusions or operational details, the full policy body and referenced LCDs should be consulted.